“The STD testing market has garnered interest of the healthcare industry due to high adoption of STD testing with increase in prevalence of sexually transmitted diseases in the developing nations. Growing incidence rates and increasing prevalence of STD, implementation of national screening programs across major geographies fuel the market growth.”
The Leading players analyzed in the STD testing market report include
- Bio-Rad Laboratories Inc.
- Becton Dickinson & Company
- Cepheid Inc.
- Roche Holdings AG
- Hologic Inc.
- Danaher Corporation
- Abbott Laboratories
- DiaSorin, and Orasure.
The global STD testing market size was $86.55 billion in 2017, and is estimated to reach $133.93 billion by 2025, registering a CAGR of 5.6% during 2017 – 2025. The research offers a comprehensive analysis on the major segments including the changing market trends, key winning policies, drivers and opportunities, and competitive scenario.
Download Sample Report at https://www.alliedmarketresearch.com/request-sample/385
The rise in implementation of national screening programs, increase in prevalence of STD and supporting reimbursement for STD testing are the factors that drives the market growth. Whereas, vast proportion of patients infected with STD in out-of-reach geographic areas, social stigma associated with patients visiting specialized STD clinics, and stringent regulatory abidance requirements for the participants of STD market, restricts the growth to certain extent. Moreover, several prospects for technology, and POC test providers in the developing economies, and decreasing number of visits to GUM clinics and specialized STD clinics are estimated to provide various opportunities to the market.
On the basis of disease type, the Chlamydia Testing segment held the highest position, accounting for more than one-fourth of the total market share in 2017 and is estimated to maintain its dominant position throughout the forecast period. This is due to the wide prevalence of chlamydia across the world. On the other hand, the Gonorrhoea segment is projected to register the highest CAGR of 8.9% by 2025.
On the basis of testing type, the laboratory testing segment contributed the major share during 2017, accounting for more than four-fifths of the total market share. This is due to the wide adoption of the method among end users. However, the point of care testing segment is estimated to grow at the highest CAGR of 7.0% during the forecast period.
Asia Pacific contributed to the highest share accounting for more than half of the total share in 2017, and is expected to continue its position by 2025. This is owing to the increase in incidences of sexually transmitted diseases across the region. Furthermore, the rise in healthcare awareness and increase in responsiveness for early screening or diagnosis of the sexually transmitted diseases have augmented the growth in various ways.
Purchase Enquiry https://www.alliedmarketresearch.com/purchase-enquiry/385
|Market size available for years||2018 – 2025|
|Base year considered||2019|
|Forecast period||2019 – 2025|
|Forecast units||Value (USD)|
|Segments covered||By Disease Type, and Location of Testing|
|Geographies covered||North America, Europe, Asia-Pacific, LAMEA|
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free: +1-800-792-5285
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060